Jay Lieberman
Allergy & Immunology · Memphis, TNNPI 1407877004
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $60,138 of the $81,008 with a category attached, or 74.2%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.8%. 2025 is the largest year on record at $38,059, 6.2 times the $6,138 reported in 2019. Among allergy & immunology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $1174.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$19K
- Aquestive Therapeutics, Inc.$19K
- Alk-abello, Inc$11K
- Novartis$9K
- Genentech, Inc.$7K
- Covis Pharma GmbH$6K
- plus $10K from 8 others
Across 82 payments — averaging $2922.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$113K
- Novartis$43K
- Biotest AG$34K
- Aimmune Therapeutics, Inc.$19K
- Leadiant Biosciences, Inc.$18K
- Aquestive Therapeutics, Inc.$4K
- plus $7K from 3 others
What the payments were for
- Consulting fees$60,13874%
- Speaking & faculty fees$13,43617%
- Travel & lodging$5,1086%
- Food & beverage$2,3263%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 19 | $19,268 |
| Aquestive Therapeutics, Inc. | 7 | $18,647 |
| Alk-abello, Inc | 11 | $11,313 |
| Novartis | 7 | $8,951 |
| Genentech, Inc. | 4 | $6,680 |
| Covis Pharma GmbH | 4 | $5,908 |
| Kaleo, Inc. | 2 | $3,975 |
| Bayer Healthcare LLC | 2 | $3,200 |
| AbbVie | 6 | $2,000 |
| Blueprint Medicines Corporation | 2 | $633 |
| Shire North American Group Inc | 1 | $200 |
| Aimmune Therapeutics, Inc. | 1 | $175 |
| Amgen(2 entities) | 2 | $40 |
| Biocryst US Sales Co., LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,008 in reported general payments places this provider in the 90th percentile of 79 allergy & immunology providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 21 | $52,754 |
| Cromolyn Sodium | 11 | $1,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $6,680 | $52,75421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Memphis
- Phillip LiebermanMemphis$131K
- Reena PatelMemphis$101K
- Amy RagsdaleMemphis$8K
- Venusa PhomakayMemphis$6K
- Phuong leMemphis$3K
- Nicholas KolinskyKnoxville$472K
- Tidence PrinceMaryville$269K
- Tammy Heinly McCulleyGermantown$165K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.